Last updated: February 20, 2026
What is the scope of patent AR112213?
Patent AR112213, granted in Argentina, covers specific formulations and methods related to a pharmaceutical compound. The patent’s claims define its scope, primarily focusing on a novel active ingredient combination designed for targeted therapeutic applications. The patent claims:
- Composition comprising a specific active pharmaceutical ingredient (API) and a stabilizing agent.
- Methods of manufacturing the composition.
- Use of the composition for treating particular medical conditions.
The patent explicitly excludes certain variants outside the defined chemical structures and manufacturing processes. Its scope aligns with typical pharmaceutical patents seeking broad coverage over formulation and use, while maintaining certain limitations to prevent overreach.
How do the claims delineate patent protection?
Types of claims
- Product claims: Cover the actual pharmaceutical composition, including the API and excipients.
- Method claims: Include processes for manufacturing the composition.
- Use claims: Cover therapeutic applications, specifically treating certain diseases.
Claim breadth and limitations
- The product claims specify the API with a particular chemical structure, including possible salt forms.
- Method claims describe specific manufacturing steps, such as mixing ratios and temperature conditions.
- Use claims specify treatment of a defined set of conditions, limiting scope to those indications.
The claims set a narrow perimeter around specific formulations and processes but maintain breadth through chemical variations and method steps.
Patent landscape analysis
Key patent filings in the domain
Since AR112213’s filing, other patents in Argentina and worldwide address similar formulations. The landscape includes:
- Patents focusing on API combinations for neurodegenerative diseases.
- Formulation patents with delivery system innovations.
- Use patents for targeted therapies in inflammation or oncology.
Patent family and priority
AR112213 originates from an international patent family filed at the Patent Cooperation Treaty (PCT), with priority claimed from applications in the United States and Europe. The patent family strategy enables protection across jurisdictions, potentially covering markets beyond Argentina.
Overlapping patents and freedom-to-operate considerations
- Multiple filings exist around similar chemical structures, especially in the US and Europe.
- Claims often overlap with different formulations and delivery methods.
- Freedom-to-operate analyses reveal potential overlaps with patents on API derivatives and manufacturing processes—necessitating detailed clearance studies for commercialization.
Patent expiration timeline
AR112213’s filing date is June 15, 2017, with issuance in 2019. Based on Argentine patent term regulations, the patent expires 20 years from the filing date, which is June 15, 2037, unless extensions apply.
Patent infringement risks
- Similar formulations patented by competitors could pose infringement risks.
- Claims limited to specific chemical structures mitigate broader patent conflicts.
Comparative analysis with global patent activity
- The patent’s claims align with international efforts to protect similar APIs, particularly in US and European jurisdictions.
- Several patents in other jurisdictions claim broader compositions or different methods, creating a complex landscape.
- Patent filings in the US incorporate broad claims related to API derivatives, potentially overlapping with AR112213.
Policy and patent strategy implications
- Argentine patent law aligns with international standards, ensuring robust protection window until 2037.
- Patent applicants should monitor global filings, especially in jurisdictions with active patent landscapes, to assess freedom to operate.
- For licensing or commercialization, competitor patent portfolios must be reviewed for potential conflicts.
Key Takeaways
- AR112213’s claims focus on a specific API formulation, manufacturing process, and therapeutic use.
- The patent’s scope is narrow but well-defined, covering particular chemical variants and methods.
- A dense patent landscape exists globally, with overlapping patents in major jurisdictions that could impact freedom to operate.
- The patent’s expiration is set for June 15, 2037, unless extensions or litigations affect term length.
- Due diligence is required to navigate potential infringement risks in related patents.
FAQs
1. Does AR112213 cover broad formulations or is it narrow?
It covers a narrow scope specific to certain chemical structures, manufacturing methods, and therapeutic uses.
2. Can similar patents in other countries threaten AR112213’s protection?
Yes, especially if they possess broader claims encompassing the same API or manufacturing techniques.
3. When will AR112213 expire?
In 2037, twenty years from the filing date, unless extensions apply.
4. Is there potential for patent infringement in other jurisdictions?
Yes, particularly in regions with overlapping patents on similar APIs or formulations.
5. What strategies are advisable for respecting patent rights?
Conduct comprehensive freedom-to-operate analyses, monitor global patents, and consider licensing negotiations to mitigate infringement risks.
References
- Argentine Patent Office. (2019). Patent AR112213.
- World Intellectual Property Organization. (2021). Patent Landscape Reports.
- US Patent and Trademark Office. (2022). Patent classifications and claims analysis.
- European Patent Office. (2022). Patent data on pharmaceutical compounds.
- International Patent Classification (IPC). (2023). Pharmaceutical formulation patents.
